PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
VKTX vs. SNDX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between VKTX and SNDX is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

VKTX vs. SNDX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Viking Therapeutics, Inc. (VKTX) and Syndax Pharmaceuticals, Inc. (SNDX). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%AugustSeptemberOctoberNovemberDecember2025
-28.16%
-39.18%
VKTX
SNDX

Key characteristics

Sharpe Ratio

VKTX:

0.86

SNDX:

-0.68

Sortino Ratio

VKTX:

2.83

SNDX:

-0.72

Omega Ratio

VKTX:

1.36

SNDX:

0.90

Calmar Ratio

VKTX:

2.17

SNDX:

-0.63

Martin Ratio

VKTX:

3.79

SNDX:

-1.67

Ulcer Index

VKTX:

34.05%

SNDX:

21.39%

Daily Std Dev

VKTX:

149.93%

SNDX:

52.25%

Max Drawdown

VKTX:

-90.41%

SNDX:

-78.98%

Current Drawdown

VKTX:

-55.92%

SNDX:

-52.38%

Fundamentals

Market Cap

VKTX:

$4.48B

SNDX:

$1.13B

EPS

VKTX:

-$0.94

SNDX:

-$3.64

PEG Ratio

VKTX:

-0.03

SNDX:

0.00

Total Revenue (TTM)

VKTX:

$0.00

SNDX:

$16.00M

Gross Profit (TTM)

VKTX:

-$236.00K

SNDX:

-$28.34M

EBITDA (TTM)

VKTX:

-$104.61M

SNDX:

-$224.46M

Returns By Period

In the year-to-date period, VKTX achieves a 3.53% return, which is significantly lower than SNDX's 4.39% return.


VKTX

YTD

3.53%

1M

-17.99%

6M

-23.07%

1Y

113.86%

5Y*

40.24%

10Y*

N/A

SNDX

YTD

4.39%

1M

-18.87%

6M

-38.86%

1Y

-39.45%

5Y*

9.32%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

VKTX vs. SNDX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VKTX
The Risk-Adjusted Performance Rank of VKTX is 8585
Overall Rank
The Sharpe Ratio Rank of VKTX is 7676
Sharpe Ratio Rank
The Sortino Ratio Rank of VKTX is 9191
Sortino Ratio Rank
The Omega Ratio Rank of VKTX is 8989
Omega Ratio Rank
The Calmar Ratio Rank of VKTX is 9191
Calmar Ratio Rank
The Martin Ratio Rank of VKTX is 7777
Martin Ratio Rank

SNDX
The Risk-Adjusted Performance Rank of SNDX is 1212
Overall Rank
The Sharpe Ratio Rank of SNDX is 1313
Sharpe Ratio Rank
The Sortino Ratio Rank of SNDX is 1616
Sortino Ratio Rank
The Omega Ratio Rank of SNDX is 1616
Omega Ratio Rank
The Calmar Ratio Rank of SNDX is 1111
Calmar Ratio Rank
The Martin Ratio Rank of SNDX is 33
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

VKTX vs. SNDX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and Syndax Pharmaceuticals, Inc. (SNDX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for VKTX, currently valued at 0.86, compared to the broader market-4.00-2.000.002.000.86-0.68
The chart of Sortino ratio for VKTX, currently valued at 2.83, compared to the broader market-4.00-2.000.002.004.002.83-0.72
The chart of Omega ratio for VKTX, currently valued at 1.36, compared to the broader market0.501.001.502.001.360.90
The chart of Calmar ratio for VKTX, currently valued at 2.17, compared to the broader market0.002.004.006.002.17-0.63
The chart of Martin ratio for VKTX, currently valued at 3.79, compared to the broader market-10.000.0010.0020.003.79-1.67
VKTX
SNDX

The current VKTX Sharpe Ratio is 0.86, which is higher than the SNDX Sharpe Ratio of -0.68. The chart below compares the historical Sharpe Ratios of VKTX and SNDX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.00AugustSeptemberOctoberNovemberDecember2025
0.86
-0.68
VKTX
SNDX

Dividends

VKTX vs. SNDX - Dividend Comparison

Neither VKTX nor SNDX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

VKTX vs. SNDX - Drawdown Comparison

The maximum VKTX drawdown since its inception was -90.41%, which is greater than SNDX's maximum drawdown of -78.98%. Use the drawdown chart below to compare losses from any high point for VKTX and SNDX. For additional features, visit the drawdowns tool.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%AugustSeptemberOctoberNovemberDecember2025
-55.92%
-52.38%
VKTX
SNDX

Volatility

VKTX vs. SNDX - Volatility Comparison

Viking Therapeutics, Inc. (VKTX) has a higher volatility of 24.09% compared to Syndax Pharmaceuticals, Inc. (SNDX) at 17.07%. This indicates that VKTX's price experiences larger fluctuations and is considered to be riskier than SNDX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%35.00%AugustSeptemberOctoberNovemberDecember2025
24.09%
17.07%
VKTX
SNDX

Financials

VKTX vs. SNDX - Financials Comparison

This section allows you to compare key financial metrics between Viking Therapeutics, Inc. and Syndax Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab